Bob Bradway, Chairman and CEO of Amgen, shared on LinkedIn:
“Amgen’s Q3 2026 results reflect continued strong performance across our business, with total revenues increasing 8% to $10.4 billion.
Seventeen medicines delivered at least double-digit sales growth, and our six key growth drivers grew 27% year over year, representing more than 70% of product sales.
It was also an important quarter for innovation, with
- positive Phase 3 results for IMDELLTRA in small cell lung cancer
- TEZSPIRE in eosinophilic esophagitis
- dazodalibep in Sjögren’s disease.
Thank you to our colleagues and partners around the world whose commitment to patients makes this progress possible every day.
Learn more about our Q3 2026 results:
Amgen delivered another strong quarter as our strategy for long-term growth continued to produce results across the enterprise.
The strength of our commercial portfolio, combined with important clinical advances and a promising late-stage pipeline, reinforces our confidence in Amgen’s ability to deliver durable growth well into the next decade.
Amgen’s Safe Harbor Statement
Amgen’s forward-looking statement outlines the risks and uncertainties that could cause actual business and financial results to differ from its projections.
Key factors include
- clinical trial outcomes
- regulatory approvals
- product commercialization
- competition from biosimilars
- pricing pressures
- reimbursement policies
- manufacturing and supply-chain disruptions
- intellectual property challenges.
The company also highlights potential impacts from government actions, economic conditions, cybersecurity incidents, litigation, and dependence on external collaborators and suppliers.
Amgen emphasizes that its projections are based on current expectations and are not guarantees of future performance.
You may also be interested in:
Amgen Announces the Appointment of David Gibbs to Its Board of Directors
Amgen Highlights New Oncology Research and Small Cell Lung Cancer Data at ESMO 2026
